Fibulin-3, a secreted glycoprotein that promotes tumor growth and invasion [18]—was first proposed as a possible MPM pleural biomarker by Pass et al. [7] with excellent capability to discriminate MM patients from non-MM patients (AUC = 0.99; sensitivity = 0.97, specificity = 0.95). Here, EFEMP1 is linked to Miyoshi myopathy.